No Data
No Data
Earnings Are Growing at China National Accord Medicines (SZSE:000028) but Shareholders Still Don't Like Its Prospects
Private Companies Account for 57% of China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Ownership, While Individual Investors Account for 28%
China National Accord Medicines Corporation Ltd. (SZSE:000028) Passed Our Checks, And It's About To Pay A CN¥0.68 Dividend
China National Accord Medicines Corporation (000028.SZ) announced a dividend of 6.8 yuan per share, a total of 10 dividends for 2023. The record date for A shares is June 24.
China National Accord Medicines Corporation (000028.SZ) announced that the company's annual equity distribution plan for 2023 is based on the current total share capital of 556,565,077 shares, with a cash dividend of 6.80 yuan per 10 shares (including tax) to all shareholders. The A-share equity registration day for this equity distribution is June 24, 2024, and the ex-dividend date is June 25, 2024. The last trading day of B-share equity distribution is June 24, 2024, and the ex-dividend date is June 25, 2024. The equity registration day is June 27, 2024.
China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Stock Is Going Strong: Is the Market Following Fundamentals?
China National Accord Medicines Corporation (000028.SZ): The company's main distribution business is aimed at public hospitals, and the safety of accounts receivable is relatively high.
China National Accord Medicines Corporation (000028.SZ) stated on the investor interaction platform on June 12 that the company's distribution business mainly targets public hospitals, and the security of accounts receivable is relatively high. The company attaches great importance to accounts receivable management, prudently handles accounts receivable aging, and accrues bad debt provisions in accordance with accounting policies.
No Data